ALX Oncology Statistics Share Statistics ALX Oncology has 53.55M
shares outstanding. The number of shares has increased by 1.47%
in one year.
Shares Outstanding 53.55M Shares Change (YoY) 1.47% Shares Change (QoQ) 0.11% Owned by Institutions (%) 62.69% Shares Floating 37.38M Failed to Deliver (FTD) Shares 21 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 1.63M, so 3.05% of the outstanding
shares have been sold short.
Short Interest 1.63M Short % of Shares Out 3.05% Short % of Float 4.85% Short Ratio (days to cover) 3.8
Valuation Ratios The PE ratio is -0.65 and the forward
PE ratio is -1.14.
ALX Oncology's PEG ratio is
0.02.
PE Ratio -0.65 Forward PE -1.14 PS Ratio 0 Forward PS 14.2 PB Ratio 0.77 P/FCF Ratio -0.71 PEG Ratio 0.02
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for ALX Oncology.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 7.26,
with a Debt / Equity ratio of 0.09.
Current Ratio 7.26 Quick Ratio 7.26 Debt / Equity 0.09 Debt / EBITDA -0.07 Debt / FCF -0.08 Interest Coverage -82.4
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-2.07M Employee Count 65 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -36.13% in the
last 52 weeks. The beta is 1.12, so ALX Oncology's
price volatility has been higher than the market average.
Beta 1.12 52-Week Price Change -36.13% 50-Day Moving Average 0.69 200-Day Moving Average 0.92 Relative Strength Index (RSI) 67.2 Average Volume (20 Days) 941,758
Income Statement
Revenue n/a Gross Profit -872K Operating Income -142.47M Net Income -134.85M EBITDA -132.25M EBIT -133.12M Earnings Per Share (EPS) -2.58
Full Income Statement Balance Sheet The company has 17.57M in cash and 9.9M in
debt, giving a net cash position of 7.66M.
Cash & Cash Equivalents 17.57M Total Debt 9.9M Net Cash 7.66M Retained Earnings -621.12M Total Assets 95.32M Working Capital 66.41M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -121.91M
and capital expenditures -447K, giving a free cash flow of -122.36M.
Operating Cash Flow -121.91M Capital Expenditures -447K Free Cash Flow -122.36M FCF Per Share -2.35
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
